Vladimir J N Bykov

List of Publications by Year
in descending order

25	4,112	394421 19	642732 23
papers	citations	h-index	g-index

26	26	26	4136
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells. Cell Death and Disease, 2021, 12, 709.	6.3	11
2	A thiolâ€bound drug reservoir enhances APRâ€246â€induced mutant p53 tumor cell death. EMBO Molecular Medicine, 2021, 13, e10852.	6.9	28
3	p53 as a hub in cellular redox regulation and therapeutic target in cancer. Journal of Molecular Cell Biology, 2019, 11, 330-341.	3.3	71
4	APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death and Disease, 2018, 9, 439.	6.3	182
5	Targeting mutant p53 for efficient cancer therapy. Nature Reviews Cancer, 2018, 18, 89-102.	28.4	655
6	The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells. Translational Oncology, 2018, 11, 1343-1349.	3.7	25
7	Needling With 5-Fluorouracil (5-FU) After XEN Gel Stent Implantation: 6-Month Outcomes. Journal of Glaucoma, 2018, 27, 893-899.	1.6	18
8	Role of Thiol Reactivity for Targeting Mutant p53. Cell Chemical Biology, 2018, 25, 1219-1230.e3.	5.2	20
9	Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246. Scientific Reports, 2018, 8, 12671.	3.3	53
10	Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors. Frontiers in Oncology, 2017, 7, 323.	2.8	22
11	Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy. Frontiers in Oncology, 2016, 6, 21.	2.8	99
12	Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Letters, 2014, 588, 2622-2627.	2.8	154
13	Targeting Mutant p53 for Improved Cancer Therapy. , 2013, , 257-273.		0
14	Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer. Journal of Clinical Oncology, 2012, 30, 3633-3639.	1.6	346
15	Mutant p53 rescue and modulation of p53 redox state. Cell Cycle, 2009, 8, 2509-2517.	2.6	43
16	PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain. Cancer Cell, 2009, 15, 376-388.	16.8	508
17	Mutant p53 targeting by the low molecular weight compound STIMAâ€1. Molecular Oncology, 2008, 2, 70-80.	4.6	91
18	Mutant p53 Reactivation as a Novel Strategy for Cancer Therapy. , 2007, , 399-419.		1

#	ARTICLE	IF	CITATIONS
19	PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis. Oncogene, 2005, 24, 3484-3491.	5.9	216
20	Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs. Journal of Biological Chemistry, 2005, 280, 30384-30391.	3.4	207
21	Novel cancer therapy by reactivation of the p53 apoptosis pathway. Annals of Medicine, 2003, 35, 458-465.	3.8	52
22	Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis, 2002, 23, 2011-2018.	2.8	152
23	Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene, 2002, 21, 2119-2129.	5.9	173
24	Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature Medicine, 2002, 8, 282-288.	30.7	981
25	Cancer Therapy by Reactivation of the p53 Apoptosis Pathway. , 0, , 891-912.		0